ACD/Labs Announces an Important Investment by Sanofi-Aventis for Production Facilities in Europe
Complete the form below to unlock access to ALL audio articles.
Advanced Chemistry Development, Inc., (ACD/Labs) recently sold a suite of NMR software to Sanofi-Aventis, for use by five of its Process Development teams in production facilities in France, Germany, and Hungary.
NMR analysis is used in drug manufacturing to help identify impurities and degradants during filing and scale-up production process, and can also be used in a quality assurance capacity to help monitor the composition of the finished product.
Sanofi-Aventis needed a solution that would allow the analytical groups at some of its European Process Development sites to support internal clients with NMR analysis. ACD/1D and 2D NMR Managers allow for off-instrument processing of analytical data and the ability to store results in a database searchable by structure as well as other parameters.
ACD/Labs’ NMR Predictors provide predictions of 1D (1H, 13C, 15N, 19F, and 31P) and 2D NMR spectra, to help in the rapid interpretation and identification of potential impurities and degradants.
“With the help of ACD/Labs software tools we expect to be able to provide results to our internal clients, more quickly and accurately than in the past,” said Philippe Cleon, Head of Structural Analysis in Process Development (Neuville, France). “We were impressed with the ease of use of the software as well as the accuracy of the results we were able to obtain with these tools.”
“Before and during the implementation process, Sanofi-Aventis will receive full technical support from our staff.” said Yves Lorrain, Director of Sales, Chemcad. Chemcad is the distributor of ACD/Labs products for parts of Western Europe, including France, Belgium, Spain, The Netherlands, Sweden, Norway, Finland, and Denmark.
